SYSTM Wealth Solutions LLC Sells 1,855 Shares of STERIS plc (NYSE:STE)

SYSTM Wealth Solutions LLC lessened its position in shares of STERIS plc (NYSE:STE) by 76.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 573 shares of the medical equipment provider’s stock after selling 1,855 shares during the period. SYSTM Wealth Solutions LLC’s holdings in STERIS were worth $126,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of STE. Vanguard Group Inc. increased its holdings in shares of STERIS by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 11,864,606 shares of the medical equipment provider’s stock worth $2,608,434,000 after purchasing an additional 53,526 shares during the period. Massachusetts Financial Services Co. MA increased its stake in STERIS by 13.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock worth $1,414,453,000 after acquiring an additional 778,613 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of STERIS by 7.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider’s stock valued at $390,880,000 after acquiring an additional 120,616 shares in the last quarter. Sustainable Growth Advisers LP raised its holdings in shares of STERIS by 23.5% in the 1st quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock valued at $333,988,000 after acquiring an additional 282,387 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its position in shares of STERIS by 29.7% during the 2nd quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock valued at $251,663,000 after acquiring an additional 263,383 shares during the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at STERIS

In other STERIS news, Director Christopher S. Holland sold 473 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the sale, the director now owns 582 shares of the company’s stock, valued at approximately $139,493.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other STERIS news, Director Christopher S. Holland sold 473 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now owns 582 shares of the company’s stock, valued at approximately $139,493.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares in the company, valued at $10,603,710. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

STERIS Price Performance

STE stock opened at $239.46 on Friday. The firm has a market cap of $23.62 billion, a P/E ratio of 62.69 and a beta of 0.83. The firm’s fifty day moving average is $235.95 and its 200 day moving average is $225.52. STERIS plc has a 52 week low of $195.47 and a 52 week high of $248.24. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33.

STERIS (NYSE:STE) last announced its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.16. The firm had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The company’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period last year, the firm earned $2.00 earnings per share. Research analysts predict that STERIS plc will post 9.05 earnings per share for the current year.

STERIS Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 20th. Stockholders of record on Thursday, September 5th will be issued a $0.57 dividend. This is a boost from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, September 5th. This represents a $2.28 annualized dividend and a dividend yield of 0.95%. STERIS’s dividend payout ratio (DPR) is currently 59.69%.

Wall Street Analysts Forecast Growth

STE has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. StockNews.com upgraded shares of STERIS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th. KeyCorp upped their target price on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. Stephens reissued an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research note on Wednesday, August 7th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research note on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $246.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.